Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qyuns Therapeutics CoHKSE:02509 -1.84%9 Market Cap is HK$3,940.2 Mil as of Aug. 16, 2026. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 1,423 Biotechnology companies, Qyuns Therapeutics Co ranks better than 70.27% on this metric.
Qyuns Therapeutics Co's quarterly market cap
increased
from Dec. 2024 (HK$1,638.9 Mil) to Jun. 2025 (HK$3,379.9 Mil) and
increased
from Jun. 2025 (HK$3,379.9 Mil) to Dec. 2025 (HK$4,308.2 Mil).
Qyuns Therapeutics Co's annual market cap
increased
from Dec. 2023 (HK$0.0 Mil) to Dec. 2024 (HK$1,638.9 Mil) and
increased
from Dec. 2024 (HK$1,638.9 Mil) to Dec. 2025 (HK$4,308.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Qyuns Therapeutics Co's Enterprise Value for Today is HK$3,386.3 Mil.
Qyuns Therapeutics Co (HKSE:02509) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02509 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Qyuns Therapeutics Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qyuns Therapeutics Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Qyuns Therapeutics Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Qyuns Therapeutics Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qyuns Therapeutics Co (HKSE:02509) has a Market Cap of HK$3,940.2 Mil as of Aug. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Qyuns Therapeutics Co and its competitors. According to the industry distribution chart, Qyuns Therapeutics Co ranks #423 out of 1423 companies in the Biotechnology industry, placing it in the top 29.7%.
Is Qyuns Therapeutics Co's Market Cap too high?
Qyuns Therapeutics Co's current Market Cap is HK$3,940.2 Mil. Based on the distribution chart, Qyuns Therapeutics Co ranks #423 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #423 out of 1423 companies for Market Cap. This puts Qyuns Therapeutics Co in the upper half of its industry. The industry median Market Cap is 118.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.89, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Qyuns Therapeutics Co and its competitors. For the Biotechnology industry, the median Market Cap is 118.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qyuns Therapeutics Co's current Market Cap is HK$3,940.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Market Cap of HK$3,940.2 Mil. The current Market Cap is HK$3,940.2 Mil. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Market Cap is HK$3,940.2 Mil as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score
Get the complete analysis for HKSE:02509
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02509 has been successfully added to your 
